Dr. Elizabeth Mittendorf, MD

• Surgical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Cwru University Hospital

  Residency Hospital, 1997

• Case Western Reserve University School Of Medicine

  Medical School, 1996

• Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer, 2021-09-21

• Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine, 2021-04-15

• Immunotherapy for early triple negative breast cancer: research agenda for the next decade, 2022-02-18

• Metabolic abnormalities and survival among patients with non-metastatic breast cancer, 2022-12-29

• Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer, 2019-05-01

• Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study, 2023-08-25

• Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer, 2019-07-30

• If we build it they will come: targeting the immune response to breast cancer, 2019-10-29

• Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer, 2021-10-01

• Tumor mutational burden andPTENalterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer, 2020-02-04

• Integrin avß6 - TGFß - SOX4 Pathway Drives Immune Evasion in Triple-negative Breast Cancer, 2020-12-31

• Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence, 2020-04-22

• Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial, 2023-06-21

• Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study, 2021-08-25

• 21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort, 2019-08-14

• PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens, 2023-08-02

• Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer, 2023-07-14

• Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer, 2020-08-13

• Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC), 2020-11-30

• The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy, 2019-05-06

• Investigation of parameters that determine Nano-DC vaccine transport, 2019-04-04

• Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer, 2019-10-08

• Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx®Digital Spatial Profiler, 2021-09-04

• Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer, 2020-12-14

• Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer, 2021-08-05

• A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer, 2022-05-10

• Variation in De-Escalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer, 2022-04-06

• Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer, 2022-07-01

• Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditaryBRCAmutation, 2022-09-01

• The Immunology of Hormone Receptor Positive Breast Cancer, 2021-05-11

• Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer Oncologist Perspectives on Omission of Lymph Node Biopsy in Older Women With Breast Cancer, 2022-08-24

• Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021, 2022-06-15